ondansetron has been researched along with Diathesis in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Excerpt | Relevance | Reference |
---|---|---|
"Ondansetron is currently being explored as a treatment for motion sickness due to its proven prophylactic effect on post-operative nausea, the nausea and vomiting associated with chemotherapy, and its lack of side effects." | 9.12 | High dose ondansetron for reducing motion sickness in highly susceptible subjects. ( Elkins, AN; Muth, ER, 2007) |
"Ondansetron is currently being explored as a treatment for motion sickness due to its proven prophylactic effect on post-operative nausea, the nausea and vomiting associated with chemotherapy, and its lack of side effects." | 5.12 | High dose ondansetron for reducing motion sickness in highly susceptible subjects. ( Elkins, AN; Muth, ER, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kumar, N | 1 |
Hu, WT | 1 |
Johannsen, S | 1 |
Roewer, N | 1 |
Schuster, F | 1 |
Muth, ER | 1 |
Elkins, AN | 1 |
1 trial available for ondansetron and Diathesis
Article | Year |
---|---|
High dose ondansetron for reducing motion sickness in highly susceptible subjects.
Topics: Adolescent; Adult; Analysis of Variance; Antiemetics; Dimenhydrinate; Disease Susceptibility; Dose-R | 2007 |
2 other studies available for ondansetron and Diathesis
Article | Year |
---|---|
Extrapyramidal reaction to ondansetron and propofol.
Topics: Adult; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemetics; Basal Ganglia Diseases; Di | 2009 |
Ondansetron-induced muscular contractures in malignant hyperthermia-susceptible individuals.
Topics: Adult; Disease Susceptibility; Dose-Response Relationship, Drug; Female; Humans; Male; Malignant Hyp | 2012 |